Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.80 |
|---|---|
| High | 2.22 |
| Low | 1.77 |
| Bid | 2.09 |
| Offer | 2.15 |
| Previous close | 1.87 |
| Average volume | 4.85m |
|---|---|
| Shares outstanding | 342.57m |
| Free float | 88.64m |
| P/E (TTM) | 22.24 |
| Market cap | 640.61m USD |
| EPS (TTM) | 0.0841 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- GoodRx Reports Fourth Quarter and Full Year 2025 Results
- GoodRx Expands Into Employer Market With Launch of “GoodRx Employer Direct”
- GoodRx Powers Pricing for Leading Brand Medications on TrumpRx
- GoodRx Earns HITRUST i1 Certification for the Second Consecutive Year, Reinforcing Its Commitment to Protecting Healthcare Data at Scale
- GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
- Surescripts and GoodRx Partner to Advance Patient Price Transparency
- GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies
- GoodRx Now Offers Novo Nordisk’s Cash Price for the Launch of the Wegovy® Pill
- GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference
More ▼
